Skip to main content

Table 2 Non-hematologic criteria for dose delay and dose modification of sorafenib (except for skin toxicity)#

From: Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study

Grade

Dose Delay

Dose Modification

Grade 0-2

Treat on time

No Change

Grade 3

Delay* until ≤ Grade 2

Decrease one dose level^

Grade 4

  
  1. #: Also excludes nausea/vomiting that has not been premedicated, and diarrhea.
  2. *: If no recovery after 30-day delay, treatment will be discontinued.
  3. ^: If more than 2 dose reductions are required, treatment will be discontinued.
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us